SARS-CoV-2 genomic surveillance in Geneva: bi-weekly update

Caveat:
- Since January 2023, only a limited number of samples (up to 30) from the Geneva area are sequenced weekly. Therefore, the biweekly data published by our laboratory might provide some trends regarding local epidemiology but are not optimally representative. Please note that in terms of representability, this data should be interpreted cautiously due to cluster effects.

Highlights:
- The number of tests done at our laboratory is slowly but progressively decreasing since the beginning of the year. The positivity rate stayed stable at a low level since January (Figure 1).
- Hospitalization rates at the HUG are stable at low levels since mid-January. The number of hospitalized patients with a SARS-CoV-2 infection increased during week 14 at the HUG because of nosocomial transmission. For more information, please refer to the weekly CH-SUR report.
- Since week 11, less than 15 samples originating from Geneva residents were sequenced each week. Of note, sequencing for week 13 is still ongoing.
- XBB.1.5-like variants replaced the previously circulating BQ.1 in February in Switzerland. XBB.1.5-like variants represented 14/15 and 12/13 samples during weeks 12 and 13 respectively. The remaining sequences are BQ.1. (Figure 2)
- No XBB.1.16 sequence has yet been identified in Geneva. Two XBB.1.16 were detected within the sequencing program in Switzerland: one in the canton of Zurich and one in the canton of Bern, sampled at the end of March 2023.

More information can be found in the monthly national surveillance report available at https://www.hug.ch/centre-maladies-virales-emergentes/programme-sequencage-national-du-sars-cov2

BQ.1 is a BA.5 derivative.

XBB is a recombinant of two Omicron sublineages: A BA.2 sublineage (BJ.1) and a BA.2.75 (BM.1.1.1) sublineage. Its breakpoint is located on the spike protein’s RBD domain (Receptor Binding Domain).

XBB.1.5-like These sublineages additionally acquired a mutation on the spike protein (486P) that increases its affinity to ACE-2 in vitro and therefore likely its transmissibility.

XBB.1.16 is currently displacing XBB.1.5 in many countries. This sublineage differs from XBB.1.5-like by having other mutations, some of them (S:K478R) also observed in other XBB sublineages.
Follow-up of previous updates in Geneva

The laboratory of virology of the Geneva University Hospitals as a sentinel site for the Geneva area

The number of tests (PCR and antigen tests) performed at the Geneva University Hospitals represented around 64% (591/924), and 45% (511/1136) of the total number of tests performed in the canton of Geneva during weeks 13 and 14 of 2023, respectively. Roughly 78% (86/110) and 50% (63/125) of the positive specimens collected in the Geneva area were processed at HUG during weeks 13 and 14, respectively. Specimens analyzed at the HUG originate mainly from hospitalized patients.

The number of positive tests in the canton and the total number of tests done during the surveilled weeks are available on the website of the Federal Office of Public Health (COVID-19 Suisse | Coronavirus | Dashboard (admin.ch)).
Figure 2: SARS-CoV-2 lineages identified by whole-genome sequencing at HUG from samples (Ct-value ≤32) collected from Geneva residents (Sentinella specimens excluded). * Sequencing is still ongoing for week 13. A total of 141 sequences were included in this analysis. Note that sequencing has been shifted towards hospitalized patients since the beginning of 2023.

Methods and collaborations

WGS is conducted in close collaboration with the Health 2030 Genome Center in Geneva and Philippe Le Mercier from the Swiss Institute of Bioinformatics. The national genomic surveillance program has been ongoing in Switzerland since March 1, 2021, and includes specimens collected at the HUG with a Ct-value ≤32. In some instances, sequencing can be done on specimens sent by other laboratories in Switzerland within the surveillance program or by request of the cantonal physician team. Phylogenetic analysis data are produced by Nextstrain in collaboration with Richard Neher’s group at the University of Basel and analyzed by Emma Hodcroft, from the Geneva Centre for Emerging Viral Diseases and the University of Geneva. In addition, partial Sanger sequencing may be done by our laboratory.

Geographic distribution, transmission advantage estimates and exact numbers of available sequences over time in the canton of Geneva are available on the CoV Spectrum platform, run by Tanja Stadler’s group at ETH Zurich.

These reports are produced in collaboration with the Geneva Cantonal Physician team, which provides information on epidemiological links. Please refer to the EpiScope report (EpiScope | ge.ch) for epidemiological data.

Emma Hodcroft for the Geneva Center for Emerging Viral Diseases and University of Geneva.
Geraldine Duc for the Geneva Cantonal Physician team.